We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 10 of 204 for:    Spinocerebellar Ataxias

Identification of Biomarkers in Spinocerebellar Ataxia 3 (SCA3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03885167
Recruitment Status : Recruiting
First Posted : March 21, 2019
Last Update Posted : February 11, 2022
National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by (Responsible Party):
Henry Paulson, University of Michigan

Brief Summary:
The purpose of this study is to examine the differences in cerebral spinal fluid (CSF) and blood of patients with spinocerebellar ataxias and healthy volunteers. The goal of this project is to identify new biomarkers that are useful for characterizing spinocerebellar ataxias and identify targets for treatment or prevention of this condition.

Condition or disease Intervention/treatment
Spinocerebellar Ataxia Type 3 Other: Specimen Collection

Detailed Description:

Participants will undergo a SARA exam, a lumbar puncture and a blood draw. A lumbar puncture is a procedure in which a small amount of the spinal fluid that surrounds the brain and spinal cord is removed by inserting a needle in the lower back. Participants will be asked not to eat or drink anything (water is acceptable) for at least 6 hours before the lumbar puncture visit. For this procedure, participants will be positioned lying on their side and curled up in a ball, or sitting up and bent forward, whichever is easier. Cushions will be used to enhance comfort. The lower back region will be cleaned and disinfected with an antiseptic iodine solution. The doctor will inject local anesthetic (lidocaine, 1%) into the skin of the lower back. This may produce a transient, mild burning sensation. A very small needle will be introduced into the skin and moved into fluid-filled space around the spinal nerves coming from the spinal cord. This may produce a pressure sensation. Approximately 2 tablespoons approximately 30 ml) of fluid will be collected. The needle will be removed and a band-aid applied over the needle insertion site. Participants will be asked to remain stationary, lying on flat for about ½ hour on a bed in the research clinic. Participants will be given something to eat and drink before leaving. Strenuous physical activity should be avoided for the next 24 hours. This includes lifting, bending, doing housework and gardening, or doing exercise such as jogging or bicycle riding. The SARA (Scale for the Assessment and Rating of Ataxia) exam is a clinical scale that assesses a range of different impairments in cerebellar ataxia. The scale is made up of 8 items related to gait, stance, sitting, speech, fingerchase test, nose-finger test, fast alternating movements and heel-shin test, and takes approximately 15 minutes to complete.

The study also involves a single collection of about 3.5 tablespoons (approximately 50 ml) of blood. This blood draw may take place during a regularly scheduled visit to the neurology clinic or at the research appointment.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 200 participants
Observational Model: Case-Control
Time Perspective: Prospective
Target Follow-Up Duration: 1 Day
Official Title: Identification of Biomarkers in Spinocerebellar Ataxia 3
Actual Study Start Date : February 21, 2019
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2023

Group/Cohort Intervention/treatment
Affected Individuals with Known SCA3
In order to be eligible for this cohort, participants must have confirmed genetic testing results for Spinocerebellar Ataxia Type 3.
Other: Specimen Collection
No interventions take place as part of study participation- only specimen collection occurs for both cohorts.

Healthy Individual Control Subjects
In order to be eligible for this cohort, subjects must not have a diagnosis of Spinocerebellar Ataxia Type 3 and no major medical issues including but not limited to conditions that would cause an unsafe specimen collection.
Other: Specimen Collection
No interventions take place as part of study participation- only specimen collection occurs for both cohorts.

Primary Outcome Measures :
  1. Change in Ataxin 3 Levels in Cerebrospinal Fluid Specimens [ Time Frame: 4 Hours ]
    A lumbar puncture is performed to collect CSF.

  2. Change in Ataxin 3 Levels in Blood Plasma Specimens [ Time Frame: 4 Hours ]
    A single blood draw is completed.

Biospecimen Retention:   Samples With DNA
Approximately 2 tablespoons (approximately 30 ml) of CSF will be collected, along with a single collection of about 3.5 tablespoons (approximately 50 ml) of blood.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Within the local community and/or those associated with the National Ataxia Foundation.

Inclusion Criteria:

•Confirmed Genetic Testing of SCA3 or Healthy Volunteers

Exclusion Criteria:

  • People with:

    • unstable thyroid
    • unstable intestinal/stomach issues
    • unstable heart issues
    • unstable liver issues
    • unstable kidney issues
    • unstable lung issues
    • unstable hormone issues
    • unstable mental disorders at screening
    • a tumor or evidence of having a tumor
    • a chronic infection or any severe acute infection within 3 months prior to screening
  • People who:

    • Take anti-coagulants and NSAIDs
    • Have started any investigational medications in the last month
  • Women who are pregnant or breast feeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03885167

Layout table for location contacts
Contact: Frank Ferrari, BS 734-232-2352 frankfer@med.umich.edu
Contact: Hayley McLoughlin, PhD 734-763-3511 hayleymc@med.umich.edu

Layout table for location information
United States, Michigan
University of Michigan Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Tasha Kaiser    734-232-6247    kaisert@med.umich.edu   
Sponsors and Collaborators
University of Michigan
National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Layout table for investigator information
Principal Investigator: Henry Paulson, MD University of Michigan
Additional Information:

Layout table for additonal information
Responsible Party: Henry Paulson, Professor of Neurology, University of Michigan
ClinicalTrials.gov Identifier: NCT03885167    
Other Study ID Numbers: HUM00121991
U01NS106670 ( U.S. NIH Grant/Contract )
First Posted: March 21, 2019    Key Record Dates
Last Update Posted: February 11, 2022
Last Verified: February 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: At this time, no specific description of a sharing plan was incorporated into the approved grant, and there are no requirements that pertain to this action. Therefore, until more information is obtained as the study progresses, there is no plan to share at this time.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cerebellar Ataxia
Spinocerebellar Ataxias
Spinocerebellar Degenerations
Machado-Joseph Disease
Neurologic Manifestations
Nervous System Diseases
Cerebellar Diseases
Brain Diseases
Central Nervous System Diseases
Spinal Cord Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn